Datasheet

MAGEA4 Antibody
CATALOG NUMBER: 8191

Availability: In stock

$0.00
Product Price Options
$0.00
Specifications
Properties
Additional Info
Background

Specifications

SPECIES REACTIVITY:Human, Mouse, Rat
TESTED APPLICATIONS:ELISA, IF, IHC-P, WB
APPLICATIONS:MAGEA4 antibody can be used for detection of MAGEA4 by Western blot at 1 - 2 μg/mL. Antibody can also be used for immunohistochemistry starting at 5 μg/mL. For immunofluorescence start at 20 μg/mL.
USER NOTE:Optimal dilutions for each application to be determined by the researcher.
POSITIVE CONTROL:1) Cat. No. 1202 - A431 Cell Lysate
 2) Cat. No. 10-001 - Human Breast Tissue Slide
PREDICTED MOLECULAR WEIGHT:Predicted: 35 kDa

Observed: 45 kDa
SPECIFICITY:MAGEA4 antibody is human specific. At least four isoforms of MAGEA4 are known to exist.
IMMUNOGEN:MAGEA4 antibody was raised against a 16 amino acid peptide near the amino terminus of human MAGEA4.

The immunogen is located within the first 50 amino acids of MAGEA4.
HOST SPECIES:Rabbit

Properties

PURIFICATION:MAGEA4 antibody is affinity chromatography purified via peptide column.
PHYSICAL STATE:Liquid
BUFFER:MAGEA4 antibody is supplied in PBS containing 0.02% sodium azide.
CONCENTRATION:1 mg/mL
STORAGE CONDITIONS:MAGEA4 antibody can be stored at 4˚C for three months and -20˚C, stable for up to one year.
CLONALITY:Polyclonal
ISOTYPE:IgG
CONJUGATE:Unconjugated

Additional Info

ALTERNATE NAMES:Melanoma antigen family A4, MAGE4, MAGE-41, MAGE4A, MAGE-4 antigen, MAGE4B, MAGE-X2, MAGE-X2 antigen, Melanoma-associated antigen 4
ACCESSION NO.:NP_001011550
PROTEIN GI NO.:58530871
OFFICIAL SYMBOL:MAGEA4
GENE ID:4103

Background

BACKGROUND:MAGEA4 is a member of the melanoma-associated antigen family that consists of a number of antigens recognized by cytotoxic T lymphocytes (1). MAGEA4 may serve as a target for antitumoral vaccination and may play a role in embryonal development and tumor transformation or aspects of tumor progression. It is expressed in many tumors of several types, such as melanoma, head and neck squamous cell carcinoma, lung carcinoma and breast carcinoma and have been implicated in some hereditary disorders, such as dyskeratosis congenital (2-4).
REFERENCES: 1) Bhan S, Negi SS, Shao C, et al. BORIS binding to the promoters of cancer testis antigens, MAGEA2, MAGEA3, and MAGEA4, is associated with their transcriptional activation in lung cancer. Clin. Cancer Res. 2011; 17:4267-76.
2) Bhan S, Chuang A, Negi SS, et al. MAGEA4 induces growth in normal oral keratinocytes by inhibiting growth arrest and apoptosis. Oncol. Rep. 2012; 28:1498-502.
3) Saito T, Wada H, Yamasaki M, et al. High expression of MAGE-A4 and MHC class I antigens in tumor cells and induction of MAGE-A4 immune responses are prognostic markers of CHP-MAGE-A4 cancer vaccine. Vaccine, epub. 2014; S0264-410X(14)01217-1.
4) Zhang QM, He SJ, Shen N, et al. Overexpression of MAGE-D4 in colorectal cancer is a potentially prognostic biomarker and immunotherapy target. Int. J. Clin. Exp. Pathol. 2014; 7:3918-27.

For Research Use Only